First human age-reversal trials begin in 2026 as Life Biosciences targets blindness

01The optic nerve breakthrough: reversing blindness

Life Biosciences is starting human trials in January 2026 with an age-reversal approach aimed at the optic nerve. The first targets are glaucoma and NAION, or non-arteritic ischemic optic neuropathy—conditions in which preserving or restoring vision is clinically meaningful.

The eye is a strategic starting point. It can receive a localized injection, the treatment can be monitored directly, and researchers can study a defined tissue before attempting whole-body rejuvenation.

02How the gene therapy works: AAV delivery and doxycycline trigger

The therapy uses an adeno-associated virus, or AAV, to deliver three Yamanaka genes to the optic nerve. The genes are controlled by a doxycycline-inducible system: doxycycline, a familiar antibiotic, acts as the on-switch, while stopping it turns the program off.

The planned pattern is roughly six to eight weeks on, then off. The eye is intended to stay young after the treatment window, with retreatment if it is needed. A single injection is paired with oral doxycycline to activate the genes.

03From $2 million to $100: the cost reduction roadmap

Gene therapy is currently expensive, with reported costs of roughly $400,000 to $2 million per treatment and more than $10 million for the first human batch. That limits access even if the biology works.

The longer-term plan is to use AI to convert the reprogramming effect into a chemical or pill, potentially delivered with lipid nanoparticles. Sinclair describes a target of about $100 per month—around $3 per day—rather than a bespoke gene-therapy price.

04Primate success: 95% age reversal in green monkeys

In green monkeys, the reported treatment produced approximately 95% age reversal in the optic nerve. That preclinical result is the bridge to the human study, not a substitute for it. A primate result must still be tested for safety, dosing, durability, and functional vision in people.

The dox-inducible switch is central to that translation. Researchers need a way to control reprogramming rather than leave powerful embryonic genes permanently active.

05Clinical trial timeline: IND submission and phase one

The near-term regulatory path runs through an IND submission and a phase-one study. The first human trial is designed primarily to evaluate safety and tolerability while looking for signals in the intended eye diseases.

That sequence matters because cellular age reversal is a new therapeutic claim. The researchers must establish that the AAV delivery, doxycycline trigger, and temporary gene expression do not damage the tissue they are meant to restore.

06Beyond vision: Alzheimer’s, ALS, and whole-body rejuvenation

Sinclair says his lab has treated Alzheimer’s, ALS, muscle diseases, and MS in research settings, describing Alzheimer’s as cured and ALS as “pretty cured” in the interview’s shorthand. The broader claim is that no disease or injury has yet been found that could not be treated with reprogramming in principle.

Safety remains the boundary. Cancer cells die when reprogrammed because they recognize that their chromosomes are damaged and self-destruct, but translating that behavior into a therapy requires careful control. George Church’s lab has also reported a 109% lifespan extension in mice after an intravenous intervention, another reason whole-body work remains a major research frontier.

07The three-stage path to whole-body rejuvenation

The roadmap has three stages. Stage 1 is proof of concept in the eye for glaucoma and NAION. Stage 2 uses AI to turn the biology into chemicals or pills, with lipid nanoparticles as another delivery route, and expands toward the whole body. Stage 3 addresses multiple diseases and whole-body rejuvenation.

Sinclair’s stated mission is to make the treatment available to everybody, at pennies on the dollar. The first eye trial is therefore both a therapy study and a test of whether controlled reprogramming can move from an elegant laboratory idea into ordinary medicine.